Inventiva Pharma

We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases including oncology, non-alcoholic steatohepatitis (NASH) and obesity.

We are focused on developing innovative small molecule-based medicines. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. We build on our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings.

We are driven by this urgency to evolve our understanding of rare progressive muscle disorders. Our goal is to develop novel precision medicines to help protect and enhance muscle function. We are focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. We are currently testing our lead drug candidate for muscular dystrophy in clinical studies. Our goal is to develop innovative therapies for progressive muscle disorders, with the same boldness and courage of the patients and families. We are driven by this urgency to develop novel precision medicines for severe and rare disorders. We continue to build a leading, global biopharmaceutical company focused on rare disorders involving muscle dysfunction in order to develop transformative precision medicines to treat and possibly, someday cure rare muscle disorders. Guided by our drug discovery approach to target the muscle as an organ, we are developing novel therapeutic approaches using small molecules that target myosin to treat rare muscle disorders.

We are a clinical-stage pharmaceutical company focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases of huge unmet need. We are committed to developing better, safer, and more effective treatments that can have a real impact on the lives of our patients. Using chemical genomics driven technology, we are leveraging scientific innovations to discover and develop new medicines with better therapeutic options for patients in need.

We commit to the research and development of innovative solutions for Lysosomal disorders. This extensive expertise enables us to provide the most advanced treatments and state-of-the-art research, ensuring exceptional care for those affected by these rare diseases.

We are dedicated to being a committed partner to the families and communities impacted by rare diseases, including DMD. We are working with leading rare disease advocacy organizations to help facilitate access to treatments such as exon-skipping therapy and patient support. We are a highly focused, research-driven biopharmaceutical company working in rare diseases. At NS Pharma we believe in the potential of new therapies, such as our exon-skipping technology for DMD, to redefine the way patients and healthcare providers fight rare diseases. We aim to offer healthier futures to more patients by:. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Delivering life-changing medicines with the quality and safety that patients and caregivers can rely on. NS Pharma is fully committed to ensuring that all of our activities comply with all applicable laws and regulations.